Canna Law Blog

NOVEMBER 27, 2021

So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.”

Therapy 87

Therapy Clinical Trials DEA Microdosing 87

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. FDA granted Breakthrough Therapy designation for Spravato in 2013 and ultimately approved it for adults who have not responded to treatment after trying other antidepressant medications. Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 2013 Sep;36(9):2530-5.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

SpeedWeed

DECEMBER 28, 2018

It was fast tracked through the approval process in response to parents of severely epileptic children pushing for a way to legally use CBD, after seeing it work wonders for children profiled in a 2013 CNN documentary called Weed , hosted by Dr. Sanjay Gupta.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40